Ntm mycobacterium full details for md exams 15marks with dosage
Reading Document
Medical Text Search
Non-tuberculous mycobacteria NTM classification species clinical syndromes
Medical Text Search
NTM mycobacteria diagnosis treatment drug regimen dosage
GradeResponse
GradeResponse
Here is a comprehensive, exam-ready answer on Non-Tuberculous Mycobacteria (NTM) suitable for a 15-mark MD examination.
Non-Tuberculous Mycobacteria (NTM)
1. Introduction & Definition
Non-tuberculous mycobacteria (NTM), also called atypical mycobacteria, environmental mycobacteria, or mycobacteria other than tuberculosis (MOTT), are mycobacterial species other than M. tuberculosis complex and M. leprae. Over 190 species and subspecies are recognized, distributed ubiquitously in the environment (soil, water, animals). They are not obligate pathogens — disease depends on host susceptibility and organism virulence.
(ATS/ERS/ESCMID/IDSA Guidelines — Treatment of NTM Pulmonary Disease, p. 1)
2. Runyon Classification (Most Exam-Important)
The classic Runyon classification is based on growth rate and pigment production:
| Group | Name | Growth | Pigment | Key Species |
|---|---|---|---|---|
| I | Photochromogens | Slow | On light exposure | M. kansasii, M. marinum |
| II | Scotochromogens | Slow | In dark and light | M. scrofulaceum, M. gordonae |
| III | Non-chromogens | Slow | None | M. avium complex (MAC), M. ulcerans, M. xenopi |
| IV | Rapid growers | Fast (<7 days) | Variable | M. abscessus, M. fortuitum, M. chelonae |
3. Important Species & Their Clinical Syndromes
A. Slowly Growing NTM
1. Mycobacterium avium Complex (MAC) — M. avium + M. intracellulare
- Most common NTM pathogen in humans
- Pulmonary disease: Two forms:
- Fibrocavitary — older men with pre-existing lung disease (COPD, previous TB)
- Nodular-bronchiectatic (Lady Windermere syndrome) — post-menopausal slender women, middle lobe/lingula involvement, scoliosis, pectus excavatum
- Disseminated MAC: In advanced HIV (CD4 <50/μL) — fever, night sweats, weight loss, hepatosplenomegaly, elevated ALP
- Cervical lymphadenitis: Children 1–5 years
- Hot-tub lung: Hypersensitivity pneumonitis from aerosolized MAC
2. M. kansasii
- Causes disease most similar to pulmonary TB (fibrocavitary)
- Mostly in middle-aged men with COPD
- Associated with urban tap water exposure
- Best prognosis among NTM pulmonary infections
3. M. xenopi
- Slow grower, thermophilic (grows at 42°C)
- Pulmonary disease, mostly in Europe and Canada
- Associated with hospital water systems
4. M. marinum
- "Fish tank granuloma" / "Swimming pool granuloma"
- Papulonodular skin lesion on hand/fingers progressing proximally (sporotrichoid pattern)
- Linked to fish tank cleaning, saltwater exposure
5. M. scrofulaceum
- Scrofula — cervical lymphadenitis in children (now largely replaced by MAC)
6. M. ulcerans
- Buruli ulcer — painless, progressive, necrotizing skin ulcer (Africa/Australia)
- Produces mycolactone toxin causing tissue destruction
7. M. haemophilum
- Skin lesions, lymphadenitis in immunocompromised patients
B. Rapidly Growing NTM
8. M. abscessus
- Most pathogenic rapid grower
- Pulmonary disease (especially in cystic fibrosis, bronchiectasis)
- Skin/soft tissue infections post-surgical procedures, liposuction
- Most drug-resistant NTM; treatment challenging
9. M. fortuitum
- Post-surgical wound infections, catheter-related infections, nail salon footbaths (furunculosis)
- Relatively more drug-sensitive
10. M. chelonae
- Disseminated skin/soft tissue infections in immunosuppressed
- LASIK keratitis
4. Pathogenesis & Risk Factors
Acquisition: Inhalation, ingestion, or direct inoculation from environmental sources — NO human-to-human transmission.
Host risk factors:
- Pulmonary: COPD, bronchiectasis, prior TB, cystic fibrosis, silicosis, scoliosis/pectus excavatum
- Immunocompromised: HIV/AIDS (especially MAC dissemination at CD4 <50), organ transplants, TNF-α inhibitors
- Genetic: IFN-γ/IL-12 pathway defects, CFTR mutations, STAT3 mutations
- Structural: Lady Windermere phenotype (slender, scoliotic, MVP)
- Local trauma: Skin/soft tissue NTM (M. fortuitum, M. chelonae, M. abscessus)
5. Diagnosis
A. ATS/IDSA Diagnostic Criteria for NTM Pulmonary Disease (all must be met)
Clinical criteria (one of):
- Pulmonary symptoms (cough, sputum, dyspnea)
- Nodular or cavitary opacities on CXR OR HRCT showing bronchiectasis with multiple small nodules
Microbiological criteria (one of):
- Positive culture from ≥2 separate sputum samples, OR
- Positive culture from ≥1 bronchoscopic wash/lavage, OR
- Positive culture from transbronchial or lung biopsy + NTM histopathological features (granuloma) or positive culture, OR
- Culture from sterile site (blood, lymph node, etc.) is automatically diagnostic
B. Laboratory Tests
- AFB smear & culture: Sputum × 3 (early morning)
- BACTEC/MGIT liquid culture: Faster isolation
- Species identification: Biochemical tests, HPLC of mycolic acids, 16S rRNA gene sequencing, Line Probe Assay (GenoType Mycobacterium CM/AS)
- Drug susceptibility testing (DST): Mandatory for MAC (macrolides), M. kansasii (rifampicin), RGM (amikacin, macrolides, quinolones)
- HRCT chest: Nodular-bronchiectatic pattern (tree-in-bud), fibrocavitary pattern
- Blood cultures (lysis-centrifugation): For disseminated MAC in HIV
C. Radiology
| Pattern | Association |
|---|---|
| Fibrocavitary (upper lobe) | MAC, M. kansasii |
| Nodular-bronchiectasis (middle lobe/lingula) | MAC (Lady Windermere) |
| Hypersensitivity pneumonitis (diffuse) | Hot-tub lung |
| Tree-in-bud nodules | MAC, M. abscessus |
6. Treatment (With Dosages)
A. MAC Pulmonary Disease
(ATS/IDSA/ERS/ESCMID 2020 Guidelines)
Non-severe nodular-bronchiectatic disease — Intermittent (3×/week) regimen:
| Drug | Dose (3× per week) |
|---|---|
| Azithromycin | 500 mg 3×/week (preferred over clarithromycin) |
| Rifampicin | 600 mg 3×/week |
| Ethambutol | 25 mg/kg 3×/week |
Severe/fibrocavitary disease — Daily regimen:
| Drug | Daily Dose |
|---|---|
| Azithromycin | 250–500 mg/day |
| OR Clarithromycin | 500 mg twice daily |
| Rifampicin | 450–600 mg/day |
| Ethambutol | 15 mg/kg/day |
| ± Amikacin IV (initial 2–3 months for cavitary/severe) | 10–15 mg/kg/day (aim peak 20–30 μg/mL) |
Duration: Until 12 months of culture negativity (usually 18–24 months total)
Amikacin liposome inhalation suspension (ALIS) — Arikayce: 590 mg once daily (add-on for refractory MAC pulmonary disease; FDA-approved 2018)
B. M. kansasii Pulmonary Disease
| Drug | Dose |
|---|---|
| Isoniazid | 300 mg/day |
| Rifampicin | 600 mg/day |
| Ethambutol | 15 mg/kg/day |
- Duration: 12 months of culture negativity (usually ~18 months)
- If rifampicin-resistant: substitute clarithromycin 500 mg BD + moxifloxacin 400 mg/day
C. Disseminated MAC (HIV Patients)
Treatment:
| Drug | Dose |
|---|---|
| Clarithromycin | 500 mg twice daily (preferred) |
| OR Azithromycin | 500–600 mg/day (if clarithromycin intolerant) |
| Ethambutol | 15 mg/kg/day |
| ± Rifabutin | 300 mg/day (add for severe disease; not rifampicin — drug interactions) |
Duration: Minimum 12 months, may discontinue if CD4 >100/μL for >6 months on ART
Primary prophylaxis (CD4 <50/μL):
- Azithromycin 1200 mg once weekly OR 600 mg twice weekly
- Can discontinue when CD4 >100/μL sustained
D. M. abscessus Pulmonary Disease (Most Difficult)
Three subspecies: abscessus, massiliense (more treatable), bolletii
Initial intensive phase (2–4 months):
| Drug | Route | Dose |
|---|---|---|
| Amikacin IV | IV | 10–15 mg/kg/day or 3×/week |
| Tigecycline | IV | 50 mg twice daily |
| Imipenem | IV | 500–1000 mg every 6–8 hrs |
| ± Azithromycin | PO | 250–500 mg/day (only if macrolide-susceptible / massiliense) |
Continuation phase (oral/inhaled):
| Drug | Dose |
|---|---|
| Azithromycin | 250–500 mg/day |
| Clofazimine | 100 mg/day |
| ± Inhaled amikacin | 590 mg/day (ALIS) |
- Prognosis poor; surgical resection considered for localized disease
- Culture conversion rare for M. abscessus subsp. abscessus due to inducible macrolide resistance (erm(41) gene)
E. M. marinum (Fish Tank Granuloma)
| Drug | Dose | Duration |
|---|---|---|
| Clarithromycin | 500 mg twice daily | 3–4 months |
| + Ethambutol | 15 mg/kg/day | 3–4 months |
| OR Doxycycline | 100 mg twice daily | 3–4 months |
| OR Co-trimoxazole | 960 mg twice daily | 3–4 months |
| OR Rifampicin + Ethambutol combination | Standard doses | 3–4 months |
F. M. ulcerans (Buruli Ulcer)
| Drug | Dose | Duration |
|---|---|---|
| Rifampicin | 10 mg/kg/day (max 600 mg) | 8 weeks |
| + Clarithromycin | 7.5 mg/kg BD (max 500 mg BD) | 8 weeks |
| OR + Streptomycin IM | 15 mg/kg/day | 8 weeks |
G. Rapidly Growing Mycobacteria (M. fortuitum, M. chelonae)
| Drug | Dose |
|---|---|
| Amikacin | 10–15 mg/kg/day IV |
| Clarithromycin | 500 mg twice daily |
| Imipenem | 500 mg every 6 hrs IV |
| Moxifloxacin | 400 mg/day |
| Linezolid | 600 mg/day |
Duration: 4–6 months for pulmonary; 3–6 months for skin/soft tissue after debridement
7. Key Points: NTM vs Tuberculosis
| Feature | NTM | TB |
|---|---|---|
| Source | Environment (soil, water) | Human-to-human |
| Transmission | No person-to-person | Droplet nuclei |
| TST/IGRA | Often weakly positive/negative | Usually positive |
| Notification | Not notifiable (most countries) | Notifiable |
| Standard ATT | Ineffective (isoniazid-resistant mostly) | Effective |
| Isolation | Not required | Required initially |
8. Complications
- Lung disease: Progressive cavitation, bronchiectasis, respiratory failure
- Dissemination (immunocompromised): Bacteremia, hepatosplenomegaly, anemia
- Drug toxicity: Ethambutol (optic neuritis), aminoglycosides (ototoxicity, nephrotoxicity), macrolides (QTc prolongation)
- Immune reconstitution inflammatory syndrome (IRIS): In HIV patients starting ART
9. Infection Control & Prevention
- No isolation needed (no human-to-human spread)
- MAC prophylaxis in HIV: Azithromycin 1200 mg/week when CD4 <50/μL
- Avoid hot tubs / exposure to contaminated water in susceptible individuals
- Proper sterilization of medical equipment
10. High-Yield Exam Summary Table
| Species | Disease | Treatment | Duration |
|---|---|---|---|
| MAC | Pulmonary, disseminated (HIV), lymphadenitis | Azithromycin + Rifampicin + Ethambutol | Till 12 months culture-negative |
| M. kansasii | Pulmonary (TB-like) | INH + Rifampicin + Ethambutol | 18 months |
| M. abscessus | Pulmonary (CF/bronchiectasis) | Amikacin + Tigecycline + Imipenem ± Azithromycin | Long-term |
| M. marinum | Fish tank granuloma | Clarithromycin + Ethambutol or Doxycycline | 3–4 months |
| M. ulcerans | Buruli ulcer | Rifampicin + Clarithromycin | 8 weeks |
| M. fortuitum | Wound, catheter infections | Amikacin + Clarithromycin | 4–6 months |
| M. scrofulaceum | Cervical lymphadenitis | Surgical excision ± Macrolide | — |
Reference: ATS/ERS/ESCMID/IDSA Official Clinical Practice Guidelines — Treatment of Nontuberculous Mycobacterial Pulmonary Disease (p. 1); supplemented with Harrison's Principles of Internal Medicine, Mandell's Principles and Practice of Infectious Diseases, and WHO Buruli Ulcer Treatment Guidelines.
This is a shared conversation. Sign in to Orris to start your own chat.